Genetic
MELPIDA
MELPIDA is a genetic therapy with 3 clinical trials. Currently 3 active trials ongoing.
Total Trials
3
Max Phase
—
Type
GENETIC
Molecule
—
Success Metrics
Active Trials
3(100%)
Phase Distribution
Ph phase_1
2
67%
Ph phase_3
1
33%
Phase Distribution
2
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 3Large-scale testing
1(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Recruiting2
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
3
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 12 (66.7%)
Phase 31 (33.3%)
Trials by Status
recruiting267%
active_not_recruiting133%
Recent Activity
3 active trials
Showing 3 of 3
recruitingphase_3
Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls.
NCT06692712
active_not_recruitingphase_1
Administration of MELPIDA to Determine the Safety and Efficacy for Patients With Spastic Paraplegia Type 50
NCT06069687
recruitingphase_1
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)
NCT05518188
Clinical Trials (3)
Showing 3 of 3 trials
NCT06692712Phase 3
Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls.
NCT06069687Phase 1
Administration of MELPIDA to Determine the Safety and Efficacy for Patients With Spastic Paraplegia Type 50
NCT05518188Phase 1
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)
All 3 trials loaded
Drug Details
- Intervention Type
- GENETIC
- Total Trials
- 3